Advertisement

Mycopathologia

, Volume 163, Issue 3, pp 137–143 | Cite as

In vitro activity of eugenol against Candida albicans biofilms

  • Miao He
  • Minquan Du
  • Mingwen Fan
  • Zhuan Bian
Article

Abstract

Most manifestations of candidiasis are associated with biofilm formation occurring on the surfaces of host tissues and medical devices. Candida albicans is the most frequently isolated causative pathogen of candidiasis, and the biofilms display significantly increased levels of resistance to the conventional antifungal agents. Eugenol, the major phenolic component of clove essential oil, possesses potent antifungal activity. The aim of this study was to investigate the effects of eugenol on preformed biofilms, adherent cells, subsequent biofilm formation and cell morphogenesis of C. albicans. Eugenol displayed in vitro activity against C. albicans cells within biofilms, when MIC50 for sessile cells was 500 mg/L. C. albicans adherent cell populations (after 0, 1, 2 and 4 h of adherence) were treated with various concentrations of eugenol (0, 20, 200 and 2,000 mg/L). The extent of subsequent biofilm formation were then assessed with the tetrazolium salt reduction assay. Effect of eugenol on morphogenesis of C. albicans cells was observed by scanning electron microscopy (SEM). The results indicated that the effect of eugenol on adherent cells and subsequent biofilm formation was dependent on the initial adherence time and the concentration of this compound, and that eugenol can inhibit filamentous growth of C. albicans cells. In addition, using human erythrocytes, eugenol showed low hemolytic activity. These results indicated that eugenol displayed potent activity against C. albicans biofilms in vitro with low cytotoxicity and therefore has potential therapeutic implication for biofilm-associated candidal infections.

Keywords

biofilm Candida albicans clove essential oil eugenol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jarvis, WR 1995Epidemiology of nosocomial fungal infections, with emphasis on Candida speciesClin Infect Dis2015261530PubMedGoogle Scholar
  2. 2.
    Ramage, G, Vandewalle, K, Wickes, BL, Lopez-Ribot, JL 2001Characteristics of biofilm formation by Candida albicans Rev Iberoam Micol18163170PubMedGoogle Scholar
  3. 3.
    Sandven, P 2000Epidemiology of candidemiaRev Iberoam Micol177381PubMedGoogle Scholar
  4. 4.
    Bachmann, SP, VandeWalle, K, Ramage, G, Patterson, TF, Wickes, BL, Graybill, JR, Lopez-Ribot, JL 2002In vitro activity of caspofungin against Candida albicans biofilmsAntimicrob Agents Chemother4635913596PubMedCrossRefGoogle Scholar
  5. 5.
    Alexander, BD, Perfect, JR 1997Antifungal resistance trends towards the year 2000. Implications for therapy and new approachesDrugs54657678PubMedGoogle Scholar
  6. 6.
    Donlan, RM 2001Biofilm formation: a clinically relevant microbiological processClin Infect Dis3313871392PubMedCrossRefGoogle Scholar
  7. 7.
    Douglas, LJ 2003 Candida biofilms and their role in infectionTrends Microbiol113036PubMedCrossRefGoogle Scholar
  8. 8.
    Kojic, EM, Darouiche, RO 2004 Candida infections of medical devicesClin Microbiol Rev17255267PubMedCrossRefGoogle Scholar
  9. 9.
    Ramage, G, Saville, SP, Thomas, DP, Lopez-Ribot, JL 2005 Candida biofilms: an updateEukaryot Cell4633638PubMedCrossRefGoogle Scholar
  10. 10.
    Chami, N, Bennis, S, Chami, F, Aboussekhra, A, Remmal, A 2005Study of anticandidal activity of carvacrol and eugenol in vitro and in vivoOral Microbiol Immunol20106111PubMedCrossRefGoogle Scholar
  11. 11.
    Situ, H, Bobek, LA 2000In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1Antimicrob Agents Chemother4414851493PubMedCrossRefGoogle Scholar
  12. 12.
    Deans, SG, Subota, KP, Kennedy, AI 1989Biological activity of plant volatile oils and their constituentsPlanta Med55588CrossRefGoogle Scholar
  13. 13.
    Janssen, AM, Scheffer, JJ, Baerheim Svendsen, A 1987Antimicrobial activity of essential oils: a 1976–1986 literature review. Aspects of the test methodsPlanta Med53395398PubMedCrossRefGoogle Scholar
  14. 14.
    Tampieri, MP, Galuppi, R, Macchioni, F, Carelle, MS, Falcioni, L, Cioni, PL, Morelli, I 2005The inhibition of Candida albicans by selected essential oils and their major componentsMycopathologia159339345PubMedCrossRefGoogle Scholar
  15. 15.
    Ou, HC, Chou, FP, Lin, TM, Yang, CH, Sheu, WH 2006Protective effects of eugenol against oxidized LDL-induced cytotoxicity and adhesion molecule expression in endothelial cellsFood Chem Toxicol4414851495PubMedCrossRefGoogle Scholar
  16. 16.
    Nangle, MR, Gibson, TM, Cotter, MA, Cameron, NE 2006Effects of eugenol on nerve and vascular dysfunction in streptozotocin-diabetic ratsPlanta Med72494500PubMedCrossRefGoogle Scholar
  17. 17.
    Guenette, SA, Beaudry, F, Marier, JF, Vachon, P 2006Pharmacokinetics and anesthetic activity of eugenol in male Sprague–Dawley ratsJ Vet Pharmacol Ther29265270PubMedCrossRefGoogle Scholar
  18. 18.
    Cassanho, AC, Fernandes, AM, Oliveira, LD, Carvalho, CA, Jorge, AO, Koga-Ito, CY 2005In vitro activity of zinc oxide-eugenol and glass ionomer cements on Candida albicans Pesqui Odontol Bras19134138PubMedGoogle Scholar
  19. 19.
    Miyakawa, Y, Mabuchi, T, Fukazawa, Y 1993New method for detection of Candida albicans in human blood by polymerase chain reactionJ Clin Microbiol3133443347PubMedGoogle Scholar
  20. 20.
    Zipkes, MR, Gilchrist, JE, Peeler, JT 1981Comparison of yeast and mold counts by spiral, pour, and streak plate methodsJ Assoc Off Anal Chem6414651469PubMedGoogle Scholar
  21. 21.
    Tortorano AM, Prigitano A, Biraghi E, Viviani MA, FIMUA-ECMM Candidaemia Study Group. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production. J Antimicrob Chemother 2005; 56: 777–779PubMedCrossRefGoogle Scholar
  22. 22.
    Wei, GX, Bobek, LA 2004In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazoleJ Antimicrob Chemother53750758PubMedCrossRefGoogle Scholar
  23. 23.
    Ramage, G, Walle, K, Wickes, BL, Lopez-Ribot, JL 2001Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilmsAntimicrob Agents Chemother4524752479PubMedCrossRefGoogle Scholar
  24. 24.
    White, TC, Marr, KA, Bowden, RA 1998Clinical, cellular, and molecular factors that contribute to antifungal drug resistanceClin Microbiol Rev11382402PubMedGoogle Scholar
  25. 25.
    Kauffman, CA, Carver, PL 1997Antifungal agents in the 1990s. Current status and future developmentsDrugs53539549PubMedCrossRefGoogle Scholar
  26. 26.
    Alem, MA, Douglas, LJ 2004Effects of aspirin and other nonsteroidal anti- inflammatory drugs on biofilms and planktonic cells of Candida albicans Antimicrob Agents Chemother484147PubMedCrossRefGoogle Scholar
  27. 27.
    Lopez-Ribot JL. Candida albicans biofilms: more than filamentation. Curr Biol 2005; 15: R453–R455PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  1. 1.Key Laboratory for Oral Biomedical Engineering of Ministry of Education, School and Hospital of StomatologyWuhan UniversityWuhanChina

Personalised recommendations